DaVita (NYSE:DVA) Price Target Cut to $90.00

DaVita (NYSE:DVA – Get Rating) had its target price reduced by stock analysts at Truist Financial from $110.00 to $90.00 in a note issued to investors on Wednesday, The Fly reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price suggests a potential upside of 15.49% from the company’s previous close.

Several other analysts have also issued reports on DVA. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 5th. Bank of America reduced their target price on DaVita from $110.00 to $90.00 and set an “underperform” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $122.00.

Shares of DVA stock opened at $77.93 on Wednesday. The stock’s fifty day simple moving average is $100.10 and its 200 day simple moving average is $107.97. The company has a debt-to-equity ratio of 8.53, a current ratio of 1.29 and a quick ratio of 1.25. The firm has a market cap of $7.37 billion, a price-to-earnings ratio of 9.28, a P/E/G ratio of 0.92 and a beta of 1.14. DaVita has a one year low of $74.97 and a one year high of $136.48.

DaVita (NYSE:DVA – Get Rating) last released its earnings results on Thursday, May 5th. The company reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.24). DaVita had a return on equity of 78.24% and a net margin of 7.78%. The firm had revenue of $2.82 billion for the quarter, compared to the consensus estimate of $2.89 billion. During the same quarter in the previous year, the firm earned $2.09 EPS. The company’s revenue was down .1% compared to the same quarter last year. On average, research analysts anticipate that DaVita will post 7.79 earnings per share for the current year.

In related news, Director Barbara J. Desoer sold 2,320 shares of the firm’s stock in a transaction on Friday, June 3rd. The stock was sold at an average price of $97.42, for a total transaction of $226,014.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.00% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Franklin Resources Inc. raised its position in shares of DaVita by 54.2% in the 3rd quarter. Franklin Resources Inc. now owns 5,172 shares of the company’s stock worth $602,000 after acquiring an additional 1,817 shares in the last quarter. Tudor Investment Corp Et Al bought a new position in shares of DaVita in the 3rd quarter worth about $6,522,000. MML Investors Services LLC raised its position in shares of DaVita by 10.6% in the 3rd quarter. MML Investors Services LLC now owns 3,258 shares of the company’s stock worth $379,000 after acquiring an additional 311 shares in the last quarter. LPL Financial LLC raised its position in shares of DaVita by 7.4% in the 3rd quarter. LPL Financial LLC now owns 17,795 shares of the company’s stock worth $2,069,000 after acquiring an additional 1,224 shares in the last quarter. Finally, United Capital Financial Advisers LLC raised its position in shares of DaVita by 21.7% in the 3rd quarter. United Capital Financial Advisers LLC now owns 2,919 shares of the company’s stock worth $339,000 after acquiring an additional 521 shares in the last quarter. 87.47% of the stock is owned by institutional investors and hedge funds.

About DaVita (Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Read More